一线GP与一线特罗凯对晚期肺腺癌的预后分析  

Prognostic analysis of GP or Tarceva as the first line therapy for advanced lung cancer

作　　者：黎焕君[1] 刘琦[1] 贾筠[1] 

机构地区：[1]东莞市人民医院肿瘤内科,广东东莞523000

出　　处：《赣南医学院学报》2017年第1期62-65,共4页JOURNAL OF GANNAN MEDICAL UNIVERSITY

摘　　要：目的:观察一线使用吉西他滨+顺铂(GP)化疗与一线使用特罗凯靶向治疗对晚期肺腺癌(EGRF突变型)患者无进展生存(PFS)及总生存(OS)的影响。方法:回顾性分析晚期肺腺癌(ⅢB、Ⅳ期)存在EGFR基因突变的57例患者的临床和随访资料,其中32例选择一线GP化疗,25例选择一线特罗凯靶向治疗,比较两组治疗患者的PFS、OS。结果:一线使用GP方案的中位PFS为11个月,一线使用特罗凯的中位PFS为12个月(P=0.028),差异有统计学意义;一线使用GP的中位OS为35个月,一线使用特罗凯的中位OS为34个月(P=0.740),差异无统计学意义。结论:对于EGFR突变的患者一线选择特罗凯治疗在PFS上优于一线选择GP化疗,但总生存时间无优势。Objective：To observe the influence of progression-frce survival （PFS） and overall survival （OS） on advanced lung cancer（EGFR mutant） after using gemcitabine ＋ cisplatin （GP） or Tareeva as the first line therapy. Methods： Retrospective analysis was made about the clinical and follow-up data of 57 patients with advanced lung cancer （ EGFR mutant, ⅢB and Ⅳ） treated in our hospital from January 2008 to December 2012 and the compared the PFS and OS. Results： Tarceva group showed a better median PFS than the GP group（ 12 months vs 11 months,P =0.028）. There was no significant differences between groups in terms of OS（ GP group：35 months vs Tarceva group ：34 months, P =0.740）. Conclusion： For patients with EGRF mutant advanced lung cancer, although there has no impact on OS, choosing targeted therapy as first-line therapy may gain more benefit on PFS than chemotherapy.

关 键 词：GP方案 特罗凯 肺腺癌 一线治疗 

分 类 号：R734.2[医药卫生—肿瘤]